Literature DB >> 20425383

Mixed myeloproliferative and myelodysplastic disorders.

Peter D Emanuel1.   

Abstract

When the French-American-British (FAB) classification system was first devised in the 1970s for the myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) was included in the FAB MDS classification schema. It always appeared out of place, however, at least when compared with the other FAB MDS categories, as CMML clearly has some features of a myeloproliferative disorder. Yet CMML also did not fit well with the traditional four myeloproliferative disorders. In the 1990s there was ongoing discussion about distinguishing a proliferative type of CMML versus a dysplastic type of CMML, based primarily on the total white blood cell count. In 2001 the World Health Organization reclassified most of the hematologic malignancies, creating a new category of mixed myelodysplastic/myeloproliferative diseases. Finally, CMML has an appropriate home, along with other disorders that seem to fit quite well in this "mixed" category.

Entities:  

Mesh:

Year:  2007        PMID: 20425383     DOI: 10.1007/s11899-007-0002-6

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   4.213


  18 in total

1.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Authors:  M Golam Mohi; Ifor R Williams; Charles R Dearolf; Gordon Chan; Jeffery L Kutok; Sarah Cohen; Kelly Morgan; Christina Boulton; Hirokazu Shigematsu; Heike Keilhack; Koichi Akashi; D Gary Gilliland; Benjamin G Neel
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

2.  Differentiating juvenile myelomonocytic leukemia from infectious disease.

Authors:  D Pinkel
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.

Authors:  M A Elliott; A Tefferi; W J Hogan; L Letendre; D A Gastineau; S M Ansell; A Dispenzieri; M A Gertz; S R Hayman; D J Inwards; M Q Lacy; I N Micallef; L F Porrata; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

Authors:  Edvardas Kaminskas; Ann Farrell; Sophia Abraham; Amy Baird; Li-Shan Hsieh; Shwu-Luan Lee; John K Leighton; Hasmukh Patel; Atiqur Rahman; Rajeshwara Sridhara; Yong-Cheng Wang; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 7.  Juvenile myelomonocytic leukemia.

Authors:  Peter D Emanuel
Journal:  Curr Hematol Rep       Date:  2004-05

8.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

Authors:  Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

9.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

10.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H Gralnick; C Sultan; C Cox
Journal:  Br J Haematol       Date:  1994-08       Impact factor: 6.998

View more
  1 in total

1.  Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.

Authors:  Dan P Zandberg; Ting-Ying Huang; Xuehua Ke; Maria R Baer; Steven D Gore; Sheila Weiss Smith; Amy J Davidoff
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.